Paul James Hoover, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Nephritis | 4 | 2020 | 304 | 1.260 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2020 | 121 | 0.660 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 323 | 0.630 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 786 | 0.550 |
Why?
|
| Drug Industry | 1 | 2020 | 756 | 0.450 |
Why?
|
| Glucocorticoids | 2 | 2017 | 2129 | 0.360 |
Why?
|
| Ion Channel Gating | 1 | 2011 | 435 | 0.340 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2761 | 0.340 |
Why?
|
| Calcium Channels | 1 | 2011 | 621 | 0.300 |
Why?
|
| Kidney | 4 | 2023 | 7152 | 0.250 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 4121 | 0.220 |
Why?
|
| Single-Cell Analysis | 3 | 2023 | 2228 | 0.200 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 5222 | 0.160 |
Why?
|
| Gene Expression Profiling | 4 | 2023 | 9431 | 0.160 |
Why?
|
| Calcium | 1 | 2011 | 5774 | 0.150 |
Why?
|
| Renal Artery | 1 | 2019 | 390 | 0.150 |
Why?
|
| Kidney Tubules | 1 | 2019 | 477 | 0.150 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2020 | 355 | 0.140 |
Why?
|
| Influenza A virus | 1 | 2020 | 466 | 0.140 |
Why?
|
| Membrane Proteins | 2 | 2020 | 7941 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2020 | 776 | 0.130 |
Why?
|
| Biopsy | 4 | 2020 | 6771 | 0.120 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 606 | 0.120 |
Why?
|
| Nephrotic Syndrome | 1 | 2018 | 400 | 0.120 |
Why?
|
| Lymphocytes | 2 | 2019 | 2617 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 1402 | 0.120 |
Why?
|
| Scleroderma, Localized | 1 | 2014 | 80 | 0.110 |
Why?
|
| Microfluidics | 1 | 2019 | 665 | 0.110 |
Why?
|
| Keratinocytes | 1 | 2017 | 792 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 2023 | 2136 | 0.100 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 2019 | 0.100 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2020 | 836 | 0.100 |
Why?
|
| Cryptosporidium parvum | 2 | 2002 | 44 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2019 | 5974 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 1483 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 575 | 0.090 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2002 | 766 | 0.090 |
Why?
|
| Fibronectins | 1 | 2014 | 728 | 0.090 |
Why?
|
| Quantitative Trait Loci | 1 | 2018 | 2049 | 0.090 |
Why?
|
| Monocytes | 1 | 2019 | 2602 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 1554 | 0.080 |
Why?
|
| Nonlinear Dynamics | 1 | 2011 | 500 | 0.080 |
Why?
|
| Psoriasis | 1 | 2017 | 913 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2016 | 3941 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2020 | 1515 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 3493 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2020 | 3518 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 2112 | 0.070 |
Why?
|
| Endoplasmic Reticulum | 1 | 2011 | 1142 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 4549 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2016 | 2099 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2018 | 4526 | 0.050 |
Why?
|
| Medicaid | 1 | 2016 | 2776 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 7852 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4228 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2002 | 6169 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2011 | 3746 | 0.050 |
Why?
|
| Thiepins | 1 | 2020 | 5 | 0.050 |
Why?
|
| Dibenzothiepins | 1 | 2020 | 8 | 0.050 |
Why?
|
| United States | 2 | 2020 | 70772 | 0.040 |
Why?
|
| Melanoma | 1 | 2018 | 5547 | 0.040 |
Why?
|
| Fibrosis | 2 | 2019 | 2028 | 0.040 |
Why?
|
| Prevalence | 1 | 2016 | 15404 | 0.040 |
Why?
|
| Humans | 15 | 2023 | 752741 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 7355 | 0.040 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2018 | 66 | 0.040 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2020 | 195 | 0.040 |
Why?
|
| Oxazines | 1 | 2020 | 304 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 17635 | 0.040 |
Why?
|
| Incidence | 1 | 2016 | 21146 | 0.040 |
Why?
|
| Triazines | 1 | 2020 | 318 | 0.040 |
Why?
|
| Methyltransferases | 1 | 2020 | 374 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2020 | 950 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2019 | 529 | 0.040 |
Why?
|
| Morpholines | 1 | 2020 | 572 | 0.030 |
Why?
|
| Apyrase | 1 | 2018 | 367 | 0.030 |
Why?
|
| Respiratory Mechanics | 1 | 2020 | 696 | 0.030 |
Why?
|
| Virus Internalization | 1 | 2020 | 500 | 0.030 |
Why?
|
| Interferons | 1 | 2019 | 720 | 0.030 |
Why?
|
| Pyridones | 1 | 2020 | 738 | 0.030 |
Why?
|
| Models, Biological | 1 | 2011 | 9569 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1875 | 0.030 |
Why?
|
| Atrophy | 1 | 2019 | 1600 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2019 | 815 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2023 | 2955 | 0.030 |
Why?
|
| Epidermis | 1 | 2017 | 530 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2023 | 21904 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 1874 | 0.030 |
Why?
|
| Bleomycin | 1 | 2014 | 513 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 73094 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2014 | 218 | 0.030 |
Why?
|
| Exercise Test | 1 | 2020 | 2090 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2019 | 2719 | 0.030 |
Why?
|
| RNA, Ribosomal, 18S | 2 | 2002 | 62 | 0.030 |
Why?
|
| Leukocytes | 1 | 2019 | 2056 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 23512 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2018 | 2332 | 0.020 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 12432 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2023 | 4041 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 2499 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 3885 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 2215 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 64017 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 6417 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 2927 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 22009 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2017 | 11553 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2018 | 4028 | 0.020 |
Why?
|
| Pyridines | 1 | 2020 | 2841 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2020 | 3012 | 0.020 |
Why?
|
| Alleles | 1 | 2018 | 6954 | 0.020 |
Why?
|
| Computational Biology | 1 | 2019 | 3531 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2019 | 3757 | 0.020 |
Why?
|
| Ligands | 1 | 2014 | 3300 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 4455 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 2005 | 0.020 |
Why?
|
| Collagen | 1 | 2014 | 2689 | 0.020 |
Why?
|
| Cell Line | 1 | 2020 | 16004 | 0.020 |
Why?
|
| Adult | 4 | 2020 | 216658 | 0.010 |
Why?
|
| Exercise | 1 | 2020 | 5662 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13364 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 20026 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 16789 | 0.010 |
Why?
|
| RNA, Protozoan | 1 | 2001 | 43 | 0.010 |
Why?
|
| Micromanipulation | 1 | 2001 | 53 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 12054 | 0.010 |
Why?
|
| DNA, Ribosomal | 1 | 2002 | 291 | 0.010 |
Why?
|
| Skin | 1 | 2014 | 4393 | 0.010 |
Why?
|
| Male | 4 | 2020 | 354311 | 0.010 |
Why?
|
| Middle Aged | 3 | 2020 | 216054 | 0.010 |
Why?
|
| Female | 4 | 2020 | 385090 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2014 | 9223 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 15657 | 0.010 |
Why?
|
| Animals | 4 | 2018 | 169600 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 14761 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 57267 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 81766 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 78758 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 86713 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 165629 | 0.000 |
Why?
|
| Genotype | 1 | 2002 | 12970 | 0.000 |
Why?
|